Torrent Pharma to buy certain generic drugs from Novartis
orrent Pharmaceuticals said it has entered into pacts with Swiss pharma major Novartis AG to acquire certain generic drugs11-04-2017
11-04-2017
Certificate Under Regulation 40 (9) For Half Year Ended March 31, 2017
Pursuant to Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we enclose herewith a Certificate from a practicing Company Secretary with respect to transfers for half year ended March 31, 2017, for your information and records11-04-2017
Board Meeting On May 23, 2017
Meeting of the Board of Directors to be held on May 23, 201731-03-2017
Torrent in talks to acquire select Novartis businesses
Deal estimated to be less than Rs 500 crore10-03-2017
Hyderabad is one of Novartis's core centres, says MD Vasant Narasimhan
The global head of drug development and chief medical officer of Novartis International on clinical trials, gene-editing tools, and role of sensors, machine learning in medicine04-03-2017
Moving talent around is core to our work: Novartis chief medical officer
International sites working on global projects needs support for innovation20-02-2017
T-Hub teams up with Novartis Healthcare to help health tech start-ups
Start-up engine, T-Hub, has signed a Memorandum of Understanding (MoU) with pharmaceutical major Novartis Healthcare Private Ltd (NHPL) to create and execute joint programmes to help health tech...09-02-2017
Divested business and price controls cut Novartis revenue and profits
Novartis India, declaring weak profits and sales, admitted that increased price controls on drugs in its category, as well as the divestment of the Animal Health business, have hit company performance. Total income from operations was down 14.5% to Rs. 164.4 crore compared to the same period last year, but net profits took a deeper hit due to new price controls on products sold, with profits falling to Rs. 13 crore this Q3 compared to Rs. 56 crore in the same period last year. The results are likely to disappoint, as the company stock was trading above key SMAs as investors expected a strong Q3.03-02-2017
Outcome of Board Meeting
Novartis India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 03, 2017, has approved the following:- Appointment of Mr. Trivikram Guda as Company Secretary and Compliance Officer with effect from February 03, 2017. A brief profile of Mr. Trivikram Guda is enclosed.03-02-2017
Dividend Distribution Policy
Novartis India Ltd has submitted to BSE a copy of Dividend Distribution Policy.03-02-2017